PharmAust's phase II monepantel trials a success
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, has released promising data in relation to its monepantel canine trial.
Management provided an interim trial update for its veterinary Phase II clinical trial investigating the anti-cancer effects of monepantel tablets in dogs with treatment naïve B cell lymphoma.
In what management conservatively termed a ‘’successful outcome’’, a total of six of seven eligible and enrolled pet canine patients have completed assessment following “at home” treatment by their owners.
One dog failed to medicate in accordance with the study protocol and was removed from trial assessment early on.
This dog, however, continued receiving monepantel tablets and has now reached over 120 days of treatment with prednisolone added to the treatment regimen by the veterinary surgeon.
50% reduction in tumour burden with majority stabilised
Following 14 days of monepantel tablet treatment, the veterinarians reported that one dog achieved a partial response with a greater than 60% reduction in total tumour burden and with one lymph node tumour regressing completely.
Four dogs achieved stable disease and progressive disease was seen in one dog.
This outcome provides a meaningful trend, comparing favourably with the treatment used in the original “liquid” monepantel formula reported on 3 December 2017, where six of seven dogs achieved stable disease and progressive disease was seen in one dog.
After 14 days treatment, one dog with progressive disease and one with a partial response, but elevated liver enzymes, discontinued monepantel tablet treatment.
All four remaining dogs completed the 28-day treatment schedule, with all achieving stable measured lymph nodes.
A new lesion, however, became apparent in two of these dogs and some elevated liver enzyme values not resulting in clinical illness were also noted.
Plasma MPL levels were recorded for all dogs and reached levels up to 50 times higher than those recorded in the human trial undertaken at the Royal Adelaide Hospital in 2014/2015.
Some variability was observed in plasma levels and, unexpectedly, at the lower blood levels of MPL there were better outcomes.
This observation may be consistent with the mechanism of action of mTOR inhibitors and lends itself to reducing and optimising the future dosing of monepantel tablets.
Paves the way for phase III trials
Commenting on these outcomes, University of Melbourne and U-Vet Werribee’s Dr Claire Cannon, the principal investigator overseeing the trial, said, “Monepantel appears to be showing anti-cancer activity in dogs with lymphoma and I believe that controlled Phase III trials are now warranted to investigate the efficacy and safety of lower dose monepantel.
‘’The Phase II trial results suggest that monepantel, perhaps in combination with standard of care lymphoma therapy, may represent a future prospect for treatment of dogs with this disease.”
Based on these findings, the Phase II trial is now on hold while an Interim Report is finalised for Elanco US Inc, highlighting both the efficacy parameters as well as the induction of inappetence and elevated liver enzymes at very high dosage levels of MPL.
In discussing the prospects of improved outcomes in phase III trials, PharmAust’s Chief Scientific Officer Dr Richard Mollard said, “Having the monepantel tablets achieve a 60% reduction in tumour burden in one dog, with one lymph node returning to normal, is a terrific and unexpected outcome.
‘’The correlation of lower MPL blood levels with superior outcomes is also a very positive trend, providing flexibility for better outcomes in a future Phase III trial.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.